News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

UAT Group Subsidiary, Ossifix Orthopedics Begins Expansion

Umbra Applied Technologies Group, Inc.

McapMediaWire -- Umbra Applied Technologies Group, Inc. (OTC: UATG ) (UAT Group) announced today that its subsidiary, Ossifix Orthopedics has begun expanding beyond Texas starting with southern and north-eastern part of the United States. Over the past several weeks, the Company has onboarded five new account managers across eleven cities in Texas with expansion into the New England area currently underway. The Company has slated the second fiscal quarter of the year for expansion across four major metropolitan cities in Louisiana and across twenty-one major metropolitan cities in Florida. Ossifix CEO, Mark Estrada, stated: “We are currently in the process of expanding operations and onboarding distribution channels in select target regions. Additionally, in Q2 we will launch two unique foot and ankle product lines.” The Company projects more than one-hundred surgeries to be completed in Q2 alone with a 20% increase month over in growth. Results from initial surgeries have demonstrated early ambulation trend with many patients driving the next day. Results of the surgeries have dramatically increased interest in the Javelin pin which formed the basis for the Company’s decision to start expansion and led to the Company to begin increasing its salesforce. Constructed of select, high-density, allograft, cortical bone, the proprietary design of the Ossifix Orthopedics Javelin pin ensures rigid fixation without pin slip or pirouetting. Manufactured of 100% allograft bone, Ossifix implants are designed for small bone, extremities, and sports medicine markets, but have applications in the craniofacial, spine and oral surgery procedures. Resorbable implant technology is readily accepted and used in today’s market, both domestically and globally. Ossifixs’ unique manufacturing process and designs yield an engineered cortical bone implant that provides secure fixation and virtually eliminates any allergic or autoimmune reactions associated with metal or plastic/polymer implants. All Ossifix Orthopedics Pin, Screw and Plate Systems are single-use surgical kits with all necessary instruments for implantation and are based on decades of clinical experience and use in the operating room. Ossifix products are designed to be used in hospitals, ambulatory surgical centers, and specialty clinics. Distribution is scheduled throughout North America, and globally in Latin America, Europe, Asia Pacific, as well as the Middle East and Africa. This global market is currently experiencing an estimated growth of 14% per year and is expected to reach $4.696 billion in sales this year. Umbra Applied Technologies Group Chief Executive Officer, Alex Umbra, commented, "The growth and interest that Ossifix has experienced is unprecedented. With the launch of their additional product suites coming later this year, Ossifix will be a disrupting force within a niche but significant market segment”. Ossifix Orthopedics will continue to meet with hospital systems, surgical centers and orthopedic surgeons across the U.S. with international sales slated to begin later this year. For more information about Ossifix Technologies go here: https://ossifixtech.com/ About Umbra Applied Technologies Group, Inc. The firm is located in Tampa Florida and focuses on advanced technologies across many disciplines. UAT Group is a holding company with interests in both public and private companies during the early stages of development as well as growth stages of companies with a synergistic business model to UAT Group subsidiaries. For more information, visit: www.uatgroup.com Investor and Media Contact: info@uatgroup.com NEITHER THE SECURITIES EXCHANGE COMMISSION NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE. Forward-Looking Information This news release may include "forward-looking statements" including forecasts, estimates, expectations, and objectives for future operations including but not limited to its ability to conclude a business combination with a third party, sale of assets, return of capital or initial public offering and a secondary listing on the OTC as a result of aforementioned and its ability to fund the exploration of its assets through the raising of equity or debt capital or through funding by a joint venture partner that are subject to a number of assumptions, risks, and uncertainties, many of which are beyond the control of Umbra Applied Technologies Group including but not limited to capital markets and securities risks and continued development success on technology. There can be and are no actual or implied guarantees that any of the above activities will be completed or completed on terms acceptable to the Company and its shareholders or approved by any regulatory authority having jurisdiction. Such forward-looking information represents management's best judgment based on information currently available. No forward-looking statement can be guaranteed and actual future results may vary materially. Umbra Applied Technologies Group does not assume the obligation to update any forward-looking statement, except as required by applicable law. Contact Details Umbra Applied Technologies Group, Inc. info@uatgroup.com

March 17, 2023 08:00 AM Eastern Daylight Time

Article thumbnail News Release

American Center for Cures Co-Founder Appointed by President Biden to National Cancer Advisory Board

The American Center for Cures

The American Center for Cures (ACC) today announced its long-time partner and co-founder Dr. Richard Boxer has been selected by President Joseph Biden to the National Cancer Advisory Board. In this role, Dr. Boxer will use his years of medical expertise to help guide the Director of the National Cancer Institute in the development of the organization’s national cancer research. Along with venerated entrepreneur Lou Weisbach, Dr. Boxer co-founded the ACC as a bipartisan initiative that aims to unite medicine, science, pharmaceuticals, business, and government to seek out new treatments and cures for Alzheimer’s, diabetes, Parkinson’s, mental diseases, many forms of cancer, and several others. “Richard Boxer and I have worked together on this important endeavor for more than a decade. It’s an honor to see him elevated to the National Cancer Advisory Board,” said Lou Weisbach, CEO and Co-Founder of ACC. “I’ve been working in a bipartisan way with leaders of both parties and the quote from Tom Price, former Secretary of Health, tells you all you need to know about our mission: ‘When this plan is approved it will rival the greatest achievements in US history and offer the sense of urgency that all American families yearn for and deserve when battling disease.’” Dr. Boxer, a UCLA Clinical Professor and Co-Founder of the American Center for Cures added: “I’ve dedicated my professional career to compassionate and uncompromising care for cancer patients and educating the public and the medical community and preventing and curing disease is a critical single issue that all Americans can agree on. As a practicing urologist treating cancer patients and cancer survivor myself, the mission of the ACC and my role in its success is very personal.” Dr. Boxer, a Clinical Professor at the David Geffen School of Medicine at UCLA, himself a three-time cancer survivor, has been practicing medicine for 44 years, caring for more than 7,000 patients with cancer and tens of thousands of patients with other illnesses. He represented the U.S. at the World Health Organization as a private citizen, a finalist for Surgeon General of the United States in both a Democratic and Republican Administration, and he was recently on the Board of Directors of the American Society of Clinical Oncology Conquer Cancer Foundation. Dr. Boxer has published nearly 100 journal articles and book chapters on medical research and has also written extensively on health policy in national press outlets. He helped create the initial clinical protocols for telemedicine, becoming the Chief Medical Officer of numerous telemedicine companies. In April 2021, he was awarded the Distinguished Alumni Award by the University of Wisconsin’s Medical School, its highest honor. “This is a critical single issue that all Americans can agree on, whether they be black or white, rich or poor, Democrat or Republican,” declared Weisbach. “With kudos to all medical breakthroughs of the past, we still haven’t gotten the job done in a business-like fashion as a nation when it comes to prevention and cures. That ends today. We are not asking congress or both parties to move forward on this initiative, we are insisting that it be passed unanimously. This issue impacts all 335 million Americans in the same way, including everyone in The White House, as well as members of Congress and their families. If we cannot unite on this issue as Americans, then I submit there are no issues on which we can unite.” About American Center for Cures The American Center for Cures (ACC) initiative is a fully funded mission to prevent, treat or cure diseases that plague every American family. The initiative will be funded by the sale of $750B bonds by the Federal Reserve, providing the capital needed to accelerate the current trajectory of medicine. Annual interest will be paid through the licensing of new compounds and drugs to pharmaceutical companies. The principal will be repaid by savings provided to the United States Government through successes in the areas of prevention and cures. The ACC business model will cost the government and taxpayers nothing, making this the single most impactful investment on behalf of the American people in the nation’s history. For more information, please visit https://theamericancenterforcures.org. Contact Details Jenna Beaucage +1 508-340-6851 jbeaucage@rainierco.com Company Website https://theamericancenterforcures.org

March 15, 2023 02:33 PM Eastern Daylight Time

Article thumbnail News Release

NuggMD Launches Leading Marijuana Telemedicine Service in Georgia

NuggMD

NuggMD, the nation's leading medical marijuana telemedicine platform, has launched its service in Georgia. For $139, Georgians can now use NuggMD’s platform to connect with a medical professional who can recommend cannabis for treatment of the state’s qualifying conditions. The launch comes amid a tense political, legal, and regulatory climate in Georgia for cannabis businesses and consumers. In 2019, Gov. Brian Kemp (R) signed into law HB 324, which legalized low-THC medical cannabis oil in the state. However, that law has yet to be successfully implemented, with only two production facilities having been awarded licenses in the subsequent four years. While newly proposed legislation, HB 196, seeks to allow more cannabis licenses, its political fate is uncertain. Additionally, Georgia remains one of the dwindling states that still impose jail time for simple possession of unlicensed cannabis. Despite lacking a single legal cannabis dispensary and the fact that no provision in Georgia law suggests how a patient might lawfully obtain cannabis, an estimated 25,000 medical cannabis patients currently reside in Georgia, and the overall demand for legal cannabis is far greater. Alex Milligan, co-founder and CMO of NuggMD, said, "Georgia still has unfair criminal statutes for the simple possession of cannabis, which runs counter to the 2019 law that legalized some forms of the substance. As one of the only services Georgians can rely on to lawfully access cannabis, the irony of this contradiction is not lost on us. One way or another—and in accordance with state law—the availability of legal cannabis will soon be a reality in Georgia. We’ve expanded our operations there so that Georgians can prepare for this eventuality by receiving cannabis recommendations from credible, licensed medical professionals.” NuggMD's platform is available from 8 am until 10 pm local time, seven days a week. No appointment is needed, and patients who are deemed not to qualify for Georgia's medical cannabis program won't be charged for their evaluation. Since its founding in 2015, NuggMD has helped more than 1,000,000 patients access medical marijuana in nearly half of the nation's states. About NuggMD NuggMD is the nation's leading medical marijuana technology platform, serving patients in California, Connecticut, Georgia, Illinois, Iowa, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nevada, New Jersey, New York, Ohio, Oklahoma, Pennsylvania, Texas, Vermont, Virginia, and West Virginia. They've connected over 1,000,000 patients face-to-face with their new medical marijuana doctors via their state-of-the-art telemedicine platform. They believe every human being has the right to explore the benefits of medical cannabis and are fully committed to helping each patient explore every option in their journey to wellness. For further information, visit NuggMD.com. Contact Details Andrew Graham andrew.g@getnugg.com Company Website http://www.nuggmd.com

March 15, 2023 02:30 PM Eastern Daylight Time

Article thumbnail News Release

BioVie Day says webinar registration now open for investors

BioVie Inc

BioVie CEO Cuong Do joins Proactive's Natalie Stoberman to share the details of the company's upcoming BioVie Day webinar on March 23. Do says BioVie Day will feature a comprehensive overview of the company’s programs in Alzheimer’s disease, Parkinson’s disease, epigenetics, longevity, and liver disease. Investors will also be able to participate in a live question and answer session will follow the leadership teams’ formal presentations. To register for BioVie Day check out this link: https://lifescievents.com/event/biovie-day/ Contact Details Proactive USA +1 347-449-0879 na-editorial@proactiveinvestors.com

March 15, 2023 10:59 AM Eastern Daylight Time

Video
Article thumbnail News Release

Spring Cleaning Your Brain Health

YourUpdateTV

Spring is almost here and it’s time to clear out the cobwebs and rethink and re-energize your health and wellness routines for the rest of the year. And while many people focus on physical health, it’s also important to think about your mental and emotional well-being. Recently, Nutrition Expert, Mia Syn, teamed with The Vitamin Shoppe on a nationwide satellite media tour to help boost your health and wellness going into Spring. A video accompanying this announcement is available at: https://youtu.be/2NqDH4Uah-A Staying Hydrated Brain health is a critical piece of your overall health that can not only improve your physical health but can also create positive cognitive and emotional impacts that contribute to overall well-being. One thing many people forget about is proper Hydration. Hydration is essential as it assists blood flow and oxygen to the brain, which helps both brain and memory function. Waterdrop is a great way to drink more water and reach your daily hydration goals. Made from natural plant and fruit extracts for flavor, Waterdrop cubes are just dropped into a glass of water and provide you with energy from caffeine, plus essential vitamins and hydration – all without sugar. They come individually wrapped so you can bring them anywhere and just drop into your refillable water bottle! Impact of Stress on the Brain Stress can have many effects on brain health and our overall health, including physical symptoms like headaches and pains, but also things like memory, mood, anxiety levels, and social behaviors. Solaray’s SHARPMIND line of supplements is formulated with clinically studied nutrients, adaptogens and nootropics, to support mental and emotional well-being. The SHARPMIND Mood formula is formulated with holy basil and reishi mushrooms to support stress and mood levels. SHARPMIND Focus has Lion’s Mane mushrooms and Bacopa to support memory and cognitive health. There are also other unique formulas for sleep, energy, and stress, to support different areas of your well-being. Optimizing Physical and Mental Performance Like other parts of your body, your brain needs proper nutrition to perform at its best whether at work, home, or on-the-go. So, whether you want to improve cognitive function, or simply feel healthier and more energetic, we need to make sure our brains are getting what they need. Focus Factor from Synergy CHC contains a clinically-tested and patented combination of neuro-nutrients plus vitamins and minerals. This formula not only helps boost your memory and focus, but it can also replace your everyday multivitamin, making it an excellent 2-for-1 supplement option to help optimize your performance throughout the day. Sleep and Aging Many of us struggle to get the quality sleep we need, and after a night of tossing and turning, we often lack the energy, confidence, and clear thinking we need to accomplish our goals. Somnapure Sleep Gummies from Force Factor can help. Their 100% drug-free, non-habit-forming formula contains a 10 mg dose of melatonin which helps you relax before bed, so you can fall asleep faster and stay asleep longer. And finally, as people age, our physical and mental performance may require more support. But there are ways for us to address these deficits and maintain our edge. Forebrain Advanced from Force Factor is formulated with brain-boosting herbs and advanced nootropics that can help you achieve better cognitive performance and improve memory and recall. For more information, visit vitaminshoppe.com About Mia Syn Mia Syn, MS, RDN is a nationally recognized nutrition expert and founder of Nutrition by Mia, a popular online wellness destination frequented by millions of readers around the globe. She holds a Master of Science in human nutrition from Columbia University and has been featured by dozens of major media outlets including Women's Health Magazine, Cosmopolitan and SHAPE. As one of the most recognized and trusted young nutritionists in the country, she has helped hundreds of her clients and millions of her readers lose weight, improve their health and develop better sustainable eating habits for life. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

March 15, 2023 09:37 AM Eastern Daylight Time

Video
Article thumbnail News Release

Aptamer Group "anticipating higher revenues" in its second half

Aptamer Group PLC

Aptamer Group PLC (AIM:APTA) CEO Dr Arron Tolley speaks to Proactive's Thomas Warner following the release of the company's interim results. Dr. Tolley gives his take on how the business performed during the first half of its financial year, adding that he is "anticipating higher revenues" in the second half. Contact Details Proactive UK Ltd Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

March 15, 2023 07:32 AM Eastern Daylight Time

Video
Article thumbnail News Release

VinBrain becomes NVIDIA Inception Premier Member

Vingroup

HANOI, VIETNAM - Media OutReach - 14 March 2023 - VinBrain has become a Premier member of NVIDIA Inception, a global program that provides cutting-edge startups with access to accelerated computing resources and more. By teaming up with NVIDIA, VinBrain is poised to transform HealthTech innovation in Southeast Asia, building on its previous successful collaborations with Microsoft and Stanford University. As a Premier member of NVIDIA Inception, VinBrain has the advantage of being an early adopter of NVIDIA's latest hardware innovations. Moreover, VinBrain receives ongoing technical support by regularly meeting with R&D experts, empowering the company to design and train advanced AI models and seamlessly integrate AI systems into clinical workflows. With this capability, VinBrain is better equipped to serve hundreds of hospitals across Vietnam, the United States, and Southeast Asian nations with optimal efficiency. VinBrain's AI product suite, including DrAid™, AIScaler™, and SenMe™ (aka AIviCare™) is now featured on the NVIDIA Accelerated Apps Catalog. “ We are thrilled to become a Premier member of NVIDIA Inception,” said Steven Truong, CEO of VinBrain. “ VinBrain has collaborated with Microsoft Corporation on data sharing, cross-validation, product research and development, and with Stanford University on in-depth research and data use, including hundreds of thousands of shared medical images. Continuing collaboration with NVIDIA in the hardware field will create a strong foundation for VinBrain to enhance quality, efficiency, and accessibility of healthcare services, bringing the best value of AI to provide effective support for patients and doctors." VinBrain has committed to NVIDIA's cutting-edge tech solutions from the outset, relying on the NVIDIA Clara healthcare platform, MONAI open-source framework, and NVIDIA NeMo framework for training, customizing and deploying generative AI models. Likewise, VinBrain has used NVIDIA DGX SuperPOD-powered AI supercomputing to develop computer vision solutions for medical imaging, intelligent video analytics, automatic speech recognition, natural language processing, and text-to-speech, resulting in 100x faster model training than with CPU only. “ VinBrain provides impactful solutions for many hospitals globally and supports healthcare professionals to augment their workflows and deliver precision radiology,” said Renee Yao, Global Healthcare AI Startups Lead at NVIDIA. “As a Premier member of NVIDIA Inception, VinBrain will work with NVIDIA to improve healthcare and precision medicine.” Healthcare has notably been one of the emerging industries in NVIDIA’s Inception, which now boasts over 1,300 healthcare startups. Steven Truong will speak at an exclusive Healthcare AI Council as part of NVIDIA GTC, a global AI conference running March 20-23, 2023 in San Francisco, US. He will share his thoughts on the future of innovation in the healthcare and life sciences industry and discuss how to collaborate globally and bring bigger impacts to improve patient outcomes and efficiency for doctors’ workflows. About VinBrain As a 4-year-old startup, Invested by Vingroup, the biggest conglomerate in Vietnam, VinBrain has a mission to infuse AI and IoT to improve people's lives and productivity. The company has developed over 300 AI models that process medical images and medical reports including X-ray, CT, MRI and medical reports data from a dataset of over 2.5 million images and big data of text. The comprehensive AI platform, DrAid™, has been deployed in over 100 hospitals in Vietnam, Myanmar, New Zealand, and the US.To learn more, visit the VinBrain website: https://vinbrain.net/ Contact Details Media Contact v.chidqd1@vingroup.net Company Website https://vinbrain.net/

March 14, 2023 09:30 AM Eastern Daylight Time

Image
Article thumbnail News Release

New Policy to Allocate Donor Lungs Takes Effect

United Network for Organ Sharing

Earlier this month, United Network for Organ Sharing (UNOS) launched a new lung allocation policy that will increase equitable access for patients who are in greatest need of a lung transplant while decreasing the overall number of patient deaths on the national waitlist. UNOS is the non-profit that contracts with the federal government to serve as the nation’s Organ Procurement and Transplantation Network (OPTN). Developed with the help of the Massachusetts Institute of Technology (MIT), RTI International (RTI) and the Scientific Registry of Transplant Recipients (SRTR), this policy is the first to use continuous distribution, which will become the standard for kidneys, pancreases, hearts, livers and other types of organ transplants in the future. This new, dynamic framework relies on a more holistic view of each patient, dissolves rigid boundaries that exist in the current, category-based system, and ensures that no single factor determines a patient’s priority on the waitlist. Donor lungs will now be allocated based on a unique composite score developed for each patient. This score will be based on a variety of factors, including illness severity, biology, expected time of life after transplant and more. “This innovative new system will be more equitable and patient-focused,” said Marie Budev, D.O., M.P.H., who serves as chair of the OPTN Lung Transplantation Committee, which spearheaded the policy development. “Instead of considering the many factors that define a candidate's unique need for an organ sequentially, we can now consider them all simultaneously for each patient.” Researchers from MIT's Sloan School of Management assisted the committee in developing the continuous distribution framework by applying artificial intelligence (AI) and machine learning to evaluate the effectiveness of millions of different policy scenario options. RTI contributed analysis, and the SRTR performed simulation modeling to validate results, remaining involved throughout the policy framework’s implementation. “Continuous distribution is a generational change in the field of organ allocation,” said James Alcorn, senior policy strategist at UNOS. “We were able to build a system that’s much nimbler than before, allowing us to identify issues and implement solutions much more quickly in the future.” As part of the policy development process, a diverse group of nearly 200 individuals representing a wide range of experiences and perspectives in donation and transplant, including patients, took part in an exercise where they shared what factors they considered most important when developing the composite score. Similar to how one turns a dial, the committee can now easily adjust the weights on the scale to further optimize the allocation system when policy changes are approved. “Take pediatric priority, for example. When we identify a certain patient group that is not appropriately prioritized, we can quickly identify the attribute they share in the system, and then adjust its weight to improve the entire system,” Alcorn said. Statistical modeling predicts that the new lung policy will not only reduce the number of patients who die waiting for a lung transplant but will also increase access to transplants for patients in need, including those with the most severe illness. A recent study by the Cleveland Clinic, in partnership with the SRTR, found that across all modeling scenarios, “the system led to improved overall measures of equity” when compared to the previous system. UNOS has hosted multiple webinars and provided resources to support patients, physicians and other donation and transplant professionals during the transitional phase. To date, hundreds of individuals have attended these public webinars. Additionally, UNOS has created patient materials that address questions for candidates on the waiting list. The OPTN Board of Directors unanimously approved the policy in December 2021. The OPTN Lung Transplantation Committee will actively monitor the new lung policy and, if needed, make recommendations for additional improvements. Work to transition all other organ types to the continuous distribution framework is proceeding, with kidney and pancreas policies anticipated next. About UNOS United Network for Organ Sharing (UNOS) is a non-profit, charitable organization that serves as the Organ Procurement and Transplantation Network (OPTN) under contract with the federal government. The OPTN helps create and define organ allocation and distribution policies that make the best use of donated organs. This process involves continuously evaluating new advances and discoveries so policies can be adapted to best serve patients waiting for transplants. All transplant programs and organ procurement organizations throughout the country are OPTN members and are obligated to follow the policies the OPTN creates for allocating organs. Contact Details United Network for Organ Sharing Anne Paschke +1 804-782-4730 anne.paschke@unos.org Company Website https://unos.org

March 14, 2023 09:17 AM Eastern Daylight Time

Video
Article thumbnail News Release

Futura Medical expects FDA approval for topical ED treatment during Q2

Futura Medical PLC

Futura Medical PLC (AIM:FUM, OTC:FAMDF) CEO James Barder speaks to Proactive's Thomas Warner after announcing the European online launch of topical erectile dysfunction (ED) treatment MED3000, under the brand name Eroxon. Barder also gives an update on the company's discussions with the FDA regarding MED3000, saying that he expects approval to come during the second quarter. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

March 14, 2023 09:02 AM Eastern Daylight Time

Video
1 ... 150151152153154 ... 306